Skip to main content

Advertisement

Log in

Estrogen and Autoimmune Disease

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Estrogenic hormones possess both immunostimulating and immunosuppressive properties. In systemic lupus erythematosus (SLE), pregnancy is associated with disease flares. In some situations, exogenous estrogen predisposes to development of new SLE, flares of preexisting SLE, and thromboses in susceptible individuals. In contrast, treatment with exogenous estrogen protects postmenopausal rheumatoid arthritis (RA) patients from active RA and osteoporosis. The search for estrogen-like compounds with anti-inflammatory properties may expand treatment options in RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nalbandian G, Kovats S (2005) Estrogen, immunity & autoimmune disease. Curr Med Chem 5:85–91

    CAS  Google Scholar 

  2. Cutolo M, Capellino S, Sulli A et al (2006) Estrogens and autoimmune disease. Ann NY Acad Sci 1089:538–547

    Article  CAS  PubMed  Google Scholar 

  3. Lang TJ (2004) Estrogen as an immunomodulator. Clin Immunol 113:224–230

    Article  CAS  PubMed  Google Scholar 

  4. Cohen-Solal JFG, Jeganathan L, Kawabata D et al (2008) Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 17:528–532

    Article  CAS  PubMed  Google Scholar 

  5. Petri M (2008) Sex hormones and systemic lupus erythematosus. Lupus 17:412–415

    Article  CAS  PubMed  Google Scholar 

  6. Maul RW, Gearhart PJ (2009) Women, autoimmunity, and cancer: a dangerous liaison between estrogen and activation-induced deaminase? J Exp Med 206:11–13

    Article  CAS  PubMed  Google Scholar 

  7. Shim G-J, Kis LL, Warner M et al (2004) Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci U S A 101:1720–1724

    Article  CAS  PubMed  Google Scholar 

  8. Bynote KK, Hackenbert JM, Korach KS et al (2008) Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB × NZW)Fl mice. Genes Immun 9:137–152

    Article  CAS  PubMed  Google Scholar 

  9. McCarty DJ, Manzi S, Medsger TA Jr et al (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270

    Article  CAS  PubMed  Google Scholar 

  10. Steinberg AD, Steinberg BJ (1985) Lupus disease activity associated with menstrual cycle. J Rheumatol 12:816–817

    CAS  PubMed  Google Scholar 

  11. Mok CC, Lau CS, Ho CT et al (1999) Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 28:357–362

    Article  CAS  PubMed  Google Scholar 

  12. Mok CC, Wong RW, Lau CS et al (1999) Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 42:1274–1280

    Article  CAS  PubMed  Google Scholar 

  13. Costenbader KH, Feskanich D, Stampfer MJ et al (2007) Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 56:1251–1262

    Article  PubMed  Google Scholar 

  14. Walker SE (2007) The importance of sex hormones in lupus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 7th edn. Williams & Wilkins, Baltimore, pp 273–285

    Google Scholar 

  15. Cooper GS, Dooley MA, Treadwell EL et al (2002) Hormonal and reproductive risk factors for development of systemic lupus erythematosus. Results of a population-based, case–control study. Arthritis Rheum 46:1830–1839

    Article  CAS  PubMed  Google Scholar 

  16. Ostensen M (1999) Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann NY Acad Sci 876:131–143

    Article  CAS  PubMed  Google Scholar 

  17. Doria A, Iaccarino L, Sarzi-Puttini P et al (2006) Estrogens in pregnancy and systemic lupus erythematosus. Ann NY Acad Sci 1069:247–256

    Article  CAS  PubMed  Google Scholar 

  18. Sanchez-Guerrero J, Karlson EW, Liang MH et al (1997) Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthrits Rheum 40:804–808

    Article  CAS  Google Scholar 

  19. Bl S, Reidenberg MM, West S et al (1994) Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 140:632–642

    Google Scholar 

  20. Petri M, Kim MY, Kalunian KC, Grossman J et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. New Engl J Med 353:2550–2558

    Article  CAS  PubMed  Google Scholar 

  21. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353:2539–2549

    Article  CAS  PubMed  Google Scholar 

  22. US Preventive Services Task Force (2005) Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Int Med 142:885–860

    Google Scholar 

  23. Sanchez-Guerrero J, Liang MH, Karlson EW et al (1995) Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Int Med 122:430–433

    CAS  PubMed  Google Scholar 

  24. Barrett C, Neylon N, Snaith ML (1986) Oestrogen-induced systemic lupus erythematosus. Br J Rheumatol 25:300–301

    Article  CAS  PubMed  Google Scholar 

  25. Calvo-Alen FM, Bertoli AM, Bastian HM et al (2007) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 13:261–265

    Article  PubMed  Google Scholar 

  26. Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Darbajal M et al (2007) Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 56:3070–3079

    Article  CAS  PubMed  Google Scholar 

  27. Buyon JP, Petri MA, Kim MY et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Int Med 142:953–962

    CAS  PubMed  Google Scholar 

  28. Grady D, Herrington D, Bittner V et al (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57

    Article  PubMed  Google Scholar 

  29. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  CAS  PubMed  Google Scholar 

  30. Huong DLT, Wechsler B, Piette J-C et al (1996) Risks of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 35:1184–1186

    Article  CAS  PubMed  Google Scholar 

  31. Casoli P, Tumiati B, La Sala G (1997) Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 24:1639–1640

    CAS  PubMed  Google Scholar 

  32. Guballa N, Sammaritano L, Schwartzman S et al (2000) Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 43:550–556

    Article  CAS  PubMed  Google Scholar 

  33. Du LTH, Wechsler B, Piette J-C (2003) Induction d’ovulation et lupus. Ann Med Interne 154:45–50

    Google Scholar 

  34. Silva CAA, Leal MM, Leone C et al (2002) Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 11:419–425

    Article  CAS  PubMed  Google Scholar 

  35. Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26:436–441

    CAS  PubMed  Google Scholar 

  36. Cutolo M, Lahita RG (2005) Estrogens and arthritis. Rheum Dis Clin N Am 31:19–27

    Article  Google Scholar 

  37. Auborn KJ, Qi M, Yan XJ et al (2003) Lifespan is prolonged in autoimmune-prone (NZB/NZW) mice fed a diet supplemented with indole-3-carbinol. J Nutr 133:3610–3613

    CAS  PubMed  Google Scholar 

  38. Apelgren LD, Bailey DL, Fouts RS et al (1996) The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRLlpr/lpr mice. Cell Immunol 173:55–63

    Article  CAS  PubMed  Google Scholar 

  39. Sthoeger ZM, Zinger H, Mozes E (2002) Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 62:341–346

    Article  Google Scholar 

  40. Peeva E, Venkatesh J, Diamond B (2005) Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 75:1415–1423

    Google Scholar 

  41. Greenstein BD, Dhaher YY, de Bridges EF (1993) Effects of an aromatase inhibitor on thymus and kidney and on oestrogen receptors in female MRL/MP-lpr/lpr mice. Lupus 2(2):221–225

    Article  CAS  PubMed  Google Scholar 

  42. Rose E, Pillsbury DM (1944) Lupus erythematosus (erythematodes) and ovarian function: observations on a possible relationship, with report of six cases. Ann Int Med 21:1022–1034

    Google Scholar 

  43. Laroche M, Borg S, Lassoued S, De Lafontan B et al (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren’s syndrome. J Rheumatol 34:2259–2263

    CAS  PubMed  Google Scholar 

  44. Cheong JL, Bucknall R (2009) Retinal vein thrombosis associated with a herbal phytoesrogen preparation in a susceptible patient. Postgrad Med J 81:266–267

    Article  Google Scholar 

  45. Bhattoa HP, Bettembuk P, Balogh A et al (2004) The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic, postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 15:396–404

    Article  CAS  PubMed  Google Scholar 

  46. Sturgess AD, Evans DT, Mackay IR et al (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11–14

    CAS  PubMed  Google Scholar 

  47. Mok CC, To CH, Mak A et al (2005) Raloxifene for postmenopausal women with systemic lupus erythematosus. A pilot randomized controlled study. Arthritis Rheum 52:3997–4002

    Article  CAS  PubMed  Google Scholar 

  48. Rider V, Li X, Peterson G, Dawson J et al (2006) Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 33:1093–1101

    CAS  PubMed  Google Scholar 

  49. Lee YJ, Shin KS, Kang SW et al (2004) Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis 63:1244–1249

    Article  CAS  PubMed  Google Scholar 

  50. Johansson M, Arlestig L, Moller B et al (2005) Oestrogen receptor alpha gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis 64:1611–1617

    Article  CAS  PubMed  Google Scholar 

  51. Abdou NI, Rider V, Greenwell C et al (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797–803

    CAS  PubMed  Google Scholar 

  52. Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600–609

    Article  CAS  PubMed  Google Scholar 

  53. Brahn E, Banquerigo MN, Lee JK et al (2008) An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 35:2119–2128

    Article  CAS  PubMed  Google Scholar 

  54. Shoenfeld Y, Zangman-Goddard G, Stojanovich L et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases. IMAJ 10:8–12

    PubMed  Google Scholar 

  55. Gerosa M, De Angelis V, Riboldi et al (2008) Rheumatoid arthritis: a female challenge. Women’s Health 4:195–201

    CAS  PubMed  Google Scholar 

  56. Sokka T, Toloza S, Cutolo M et al (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arth Res Ther 11:R7

    Google Scholar 

  57. Straub RH, Harle P, Atzeni F et al (2005) Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol 32:1253–1257

    CAS  PubMed  Google Scholar 

  58. Rovensky J, Kvetnansky R, Radikova Z et al (2005) Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 23:292–296

    CAS  PubMed  Google Scholar 

  59. Capellino S, Montagna P, Villaggio B et al (2007) Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol 26:904–909

    Google Scholar 

  60. Capellino S, Riepl B, Rauch L et al (2006) Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? Ann Rheum Dis 66:53–58

    Article  PubMed  Google Scholar 

  61. Spector TD, Hochberg MC (1989) The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytical epidemiological studies using meta-analysis. Br J Rheumatol 28(Suppl):11–12

    PubMed  Google Scholar 

  62. Hall GM, Daniels M, Huskisson EC et al (1994) A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 53:112–116

    Article  CAS  PubMed  Google Scholar 

  63. MacDonald AG, Murphy EA, Capell HA et al (1994) Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 53:54–57

    Article  CAS  PubMed  Google Scholar 

  64. Forsblad d’Elia H, Larsen A, Mattsson L et al (2003) Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheum 30:1456–1463

    Google Scholar 

  65. Forsblad d’Elia H, Mattsson L, Ohlsson C et al (2003) Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor I. Arth Res Ther 5:R202–R209

    Article  Google Scholar 

  66. Forsblad d’Elia H, Carlsten H (2008) The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand J Immunol 68:661–667

    Article  PubMed  Google Scholar 

  67. Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411

    Article  PubMed  Google Scholar 

  68. Jochems C, Lagerquist M, Hakansson C et al (2008) Long-term anti-arthritis and anti-osteopenic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 152:593–597

    Article  CAS  PubMed  Google Scholar 

  69. Harnish DC (2006) Estrogen receptor ligands in the control of pathogenic inflammation. Internat Immunol 6:1413–1423

    Article  Google Scholar 

  70. Carlsten H (2007) Interaction with estrogen receptors as treatment of arthritis and osteoporosis. In: Choi Y (ed) Osteoimmunology. Springer, New York, pp 83–92

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sara E. Walker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walker, S.E. Estrogen and Autoimmune Disease. Clinic Rev Allerg Immunol 40, 60–65 (2011). https://doi.org/10.1007/s12016-010-8199-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-010-8199-x

Keywords

Navigation